New Cervical Cancer Treatment Shows Major Breakthrough

A groundbreaking study led by University College London and funded by Cancer Research UK has demonstrated that incorporating a short course of induction chemotherapy before standard chemoradiation can significantly improve survival rates for cervical cancer. The INTERLACE phase III trial, involving 500 patients over 10 years, found that this approach reduces the risk of death by 40% and the risk of cancer recurrence by 35% over at least five years. The results, published in The Lancet, indicate the most substantial improvement in cervical cancer treatment since 1999, when CRT became standard. The findings are being hailed as a major breakthrough, with calls for the treatment regimen to be included in national and international guidelines. This new strategy is praised for using existing, approved drugs that are affordable and accessible, providing a straightforward and impactful enhancement to current treatment protocols.